Acoltremon ophthalmic solution 0.003% (AR-15512) contains a topical TRPM8 agonist and is a drug candidate seeking indication for the treatment of the signs and symptoms of dry eye disease. Phase 3 studies, COMET-2 and COMET-3, evaluated its efficacy and safety.
